Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes

The quantity of programmed cell death-ligand 1 (PD-L1) is regarded as a predicting factor of clinical response to anti-PD-1 axis immunotherapy. However, the expression of PD-L1 and its prognostic value in hepatocellular carcinoma (HCC) patients remain debated. Meanwhile, the molecular features of PD...

Full description

Bibliographic Details
Main Authors: Haotian Liao, Wen Chen, Yunlu Dai, Joseph J. Richardson, Junling Guo, Kefei Yuan, Yong Zeng, Kunlin Xie
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-09-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00883/full
_version_ 1819157085758160896
author Haotian Liao
Wen Chen
Yunlu Dai
Joseph J. Richardson
Junling Guo
Kefei Yuan
Yong Zeng
Yong Zeng
Kunlin Xie
author_facet Haotian Liao
Wen Chen
Yunlu Dai
Joseph J. Richardson
Junling Guo
Kefei Yuan
Yong Zeng
Yong Zeng
Kunlin Xie
author_sort Haotian Liao
collection DOAJ
description The quantity of programmed cell death-ligand 1 (PD-L1) is regarded as a predicting factor of clinical response to anti-PD-1 axis immunotherapy. However, the expression of PD-L1 and its prognostic value in hepatocellular carcinoma (HCC) patients remain debated. Meanwhile, the molecular features of PD-1's other ligand, namely PD-L2, as well as its correlation with clinicopathological parameters and HCC tumor microenvironment (TME), are still poorly understood. In this study, immunohistochemistry (IHC) data from 304 HCC patients were used to determine the clinicopathological features of PD-L1 and PD-L2 and their correlation with CD8+ T cells in HCC. Moreover, fresh clinical HCC samples were used to identify the immune cell subtypes expressing PD-L1 and PD-L2. By using The Cancer Genome Atlas (TCGA) dataset, we further assessed the correlation between mutation signature, copy number variation (CNV), number of neoepitopes, immune gene expression, immune/stromal cell infiltration to the expression of PD-L1 and PD-L2. While membrane expression of PD-L2 was observed in 19.1% of tumor samples, no obvious expression of PD-L1 was detected on tumor cell membranes. High expression of PD-L2 on tumor membranes and PD-L1 in immune stroma were both significantly associated with poorer overall survival (OS) and disease-free survival (DFS) outcomes. Flow cytometry analysis and immunofluorescence showed that macrophages were the main immune cell subtype expressing both PD-L1 and PD-L2. Moreover, positive expression of PD-Ls was correlated with higher CD8+ T cells infiltration in immune stroma. CNV analysis showed a similarity between PD-L1 and PD-L2 in affecting gene expression. In addition, higher levels of PD-Ls correlated with higher expression of immune related genes, enhanced cytolytic activity, and larger proportions of immune/stromal cell infiltration. Collectively, our study reveals the impact of both PD-L1 and PD-L2 on the HCC tumor microenvironment for the first time, providing insight for new therapeutic options.
first_indexed 2024-12-22T16:03:10Z
format Article
id doaj.art-e5c1c60848504fe3a67eab84a4e05e08
institution Directory Open Access Journal
issn 2234-943X
language English
last_indexed 2024-12-22T16:03:10Z
publishDate 2019-09-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj.art-e5c1c60848504fe3a67eab84a4e05e082022-12-21T18:20:39ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2019-09-01910.3389/fonc.2019.00883454038Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival OutcomesHaotian Liao0Wen Chen1Yunlu Dai2Joseph J. Richardson3Junling Guo4Kefei Yuan5Yong Zeng6Yong Zeng7Kunlin Xie8Liver Transplantation Division, Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, United StatesFaculty of Health Sciences, University of Macau, Macau, ChinaDepartment of Chemical and Biomolecular Engineering, ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of Melbourne, Parkville, VIC, AustraliaJohn A. Paulson School of Engineering and Applied Sciences, Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, United StatesLaboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, ChinaLiver Transplantation Division, Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, ChinaLaboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, ChinaLiver Transplantation Division, Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, ChinaThe quantity of programmed cell death-ligand 1 (PD-L1) is regarded as a predicting factor of clinical response to anti-PD-1 axis immunotherapy. However, the expression of PD-L1 and its prognostic value in hepatocellular carcinoma (HCC) patients remain debated. Meanwhile, the molecular features of PD-1's other ligand, namely PD-L2, as well as its correlation with clinicopathological parameters and HCC tumor microenvironment (TME), are still poorly understood. In this study, immunohistochemistry (IHC) data from 304 HCC patients were used to determine the clinicopathological features of PD-L1 and PD-L2 and their correlation with CD8+ T cells in HCC. Moreover, fresh clinical HCC samples were used to identify the immune cell subtypes expressing PD-L1 and PD-L2. By using The Cancer Genome Atlas (TCGA) dataset, we further assessed the correlation between mutation signature, copy number variation (CNV), number of neoepitopes, immune gene expression, immune/stromal cell infiltration to the expression of PD-L1 and PD-L2. While membrane expression of PD-L2 was observed in 19.1% of tumor samples, no obvious expression of PD-L1 was detected on tumor cell membranes. High expression of PD-L2 on tumor membranes and PD-L1 in immune stroma were both significantly associated with poorer overall survival (OS) and disease-free survival (DFS) outcomes. Flow cytometry analysis and immunofluorescence showed that macrophages were the main immune cell subtype expressing both PD-L1 and PD-L2. Moreover, positive expression of PD-Ls was correlated with higher CD8+ T cells infiltration in immune stroma. CNV analysis showed a similarity between PD-L1 and PD-L2 in affecting gene expression. In addition, higher levels of PD-Ls correlated with higher expression of immune related genes, enhanced cytolytic activity, and larger proportions of immune/stromal cell infiltration. Collectively, our study reveals the impact of both PD-L1 and PD-L2 on the HCC tumor microenvironment for the first time, providing insight for new therapeutic options.https://www.frontiersin.org/article/10.3389/fonc.2019.00883/fullprogrammed cell death-ligandsmacrophagetumor immune stromatumor microenvironmentanti-PD-1 axis therapyhepatocellular carcinoma
spellingShingle Haotian Liao
Wen Chen
Yunlu Dai
Joseph J. Richardson
Junling Guo
Kefei Yuan
Yong Zeng
Yong Zeng
Kunlin Xie
Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes
Frontiers in Oncology
programmed cell death-ligands
macrophage
tumor immune stroma
tumor microenvironment
anti-PD-1 axis therapy
hepatocellular carcinoma
title Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes
title_full Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes
title_fullStr Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes
title_full_unstemmed Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes
title_short Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes
title_sort expression of programmed cell death ligands in hepatocellular carcinoma correlation with immune microenvironment and survival outcomes
topic programmed cell death-ligands
macrophage
tumor immune stroma
tumor microenvironment
anti-PD-1 axis therapy
hepatocellular carcinoma
url https://www.frontiersin.org/article/10.3389/fonc.2019.00883/full
work_keys_str_mv AT haotianliao expressionofprogrammedcelldeathligandsinhepatocellularcarcinomacorrelationwithimmunemicroenvironmentandsurvivaloutcomes
AT wenchen expressionofprogrammedcelldeathligandsinhepatocellularcarcinomacorrelationwithimmunemicroenvironmentandsurvivaloutcomes
AT yunludai expressionofprogrammedcelldeathligandsinhepatocellularcarcinomacorrelationwithimmunemicroenvironmentandsurvivaloutcomes
AT josephjrichardson expressionofprogrammedcelldeathligandsinhepatocellularcarcinomacorrelationwithimmunemicroenvironmentandsurvivaloutcomes
AT junlingguo expressionofprogrammedcelldeathligandsinhepatocellularcarcinomacorrelationwithimmunemicroenvironmentandsurvivaloutcomes
AT kefeiyuan expressionofprogrammedcelldeathligandsinhepatocellularcarcinomacorrelationwithimmunemicroenvironmentandsurvivaloutcomes
AT yongzeng expressionofprogrammedcelldeathligandsinhepatocellularcarcinomacorrelationwithimmunemicroenvironmentandsurvivaloutcomes
AT yongzeng expressionofprogrammedcelldeathligandsinhepatocellularcarcinomacorrelationwithimmunemicroenvironmentandsurvivaloutcomes
AT kunlinxie expressionofprogrammedcelldeathligandsinhepatocellularcarcinomacorrelationwithimmunemicroenvironmentandsurvivaloutcomes